Anti-Human CD67 (CEACAM8) (Clone CPTC-CEACAM8-2) – Purified No Carrier Protein

Human CEACAM8 peptide sequence IIGYVISNQQITPGPAYSNR

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

FSAI140R-8C1 activity is directed against human CEACAM8 peptide sequence IIGYVISNQQITPGPAYSNR.

CPTC-CEACAM8-2

CEACAMs are Ig-related proteins involved in a wide variety of physiological processes, with specific functions dependant on the tissue of expression¹. Functions include cell adhesion, pathogen binding, angiogenesis, immune regulation, insulin receptor level regulation, hearing¹ as well as cell proliferation, survival, and tumor suppression². CEACAMs dimerize in homo- and heterophilic interactions with other CEACAMs to perform their functions. CEACAM8 dimerizes with CEACAM1 and CEACAM6 to initiate signaling for various immunomodulatory activities¹. When bound to CEACAM1, which is present on other immune cells, CEACAM8 acts as a co-stimulatory factor for B cells or inhibits TLR2 response in lung epithelial cells. When bound to CEACAM6, which is expressed on epithelial cells, neutrophils, and in inflammatory conditions, CEACAM8 blocks CEACAM6 from engaging in other cis or trans interactions with CEACAM1, CEACAM3, and CEACAM5, and thereby restricts signaling via those CEACAMs¹. CEACAM8 is attached by GPI anchor to neutrophil surfaces and cannot signal directly. Additionally, CEACAM8 does not bind to known pathogens.

FSAI140R-8C1 was generated in mouse for use in immuno-MRM assays using a synthetic peptide derived from residues 79-98 of human CEACAM8, IIGYVISNQQITPGPAYSNR³. FSAI140R-8C1 detects CEACAM8 by immunohistochemistry, NCI60 protein array, and in Western blots of HeLa and H226 cell lysates⁴. Western blotting did not detect CEAMCAM8 as recombinant protein or in A549, Jurkat, MCF7, and PBMC whole cell lysates. FSAI140R-8C1 also does not detect CEACAM8 by immunofluorescence.

CEACAM8 is expressed on neutrophils and can be released in a soluble form from intracellular stores. CEACAM8 is also expressed in leukocytes of chronic myeloid leukemia patients.

CEACAM1, CEACAM6

1 Skubitz KM. Eur J Clin Invest. 54 Suppl 2(Suppl 2):e14349. 2024.
2 Bonsor DA, Günther S, Beadenkopf R, et al. Proc Natl Acad Sci U S A. 112(44):13561-13566. 2015.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://antibodies.cancer.gov/detail/CPTC-CEACAM8-2